A clinical-stage company operating Japan’s first GMP-compliant manufacturing platform for fecal microbiota transplantation (FMT) therapies.
Metagen Therapeutics has raised $7.7M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2026.
Metagen Therapeutics's investors include Mizuho Capital, JIC Venture Growth Investments, SMBC Venture Capital, JAFCO, Dentsu Ventures.
Metagen Therapeutics is headquartered in Tsuruoka, Japan.
A clinical-stage company operating Japan’s first GMP-compliant manufacturing platform for fecal microbiota transplantation (FMT) therapies.
Metagen Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Metagen Therapeutics — Funding & Investors." VCBacked, September 30, 2026, https://www.vcbacked.co/company/metagen-therapeutics. Accessed October 17, 2026.
VCBacked. (2026). Metagen Therapeutics — Funding & Investors. Retrieved October 17, 2026, from https://www.vcbacked.co/company/metagen-therapeutics
{{cite web |title=Metagen Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/metagen-therapeutics |website=VCBacked |access-date=October 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated